These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35767240)

  • 1. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study.
    Thein D; Egeberg A; Skov L; Loft N
    JAMA Dermatol; 2022 Sep; 158(9):997-1004. PubMed ID: 35767240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.
    Waljee AK; Higgins PDR; Jensen CB; Villumsen M; Cohen-Mekelburg SA; Wallace BI; Berinstein JA; Allin KH; Jess T
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):276-284. PubMed ID: 31836320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
    Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
    BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs.
    Baggett K; Brandon TG; Xiao R; Valenzuela Z; Buckley LH; Weiss PF
    J Rheumatol; 2022 Aug; 49(8):935-941. PubMed ID: 35428721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF-α inhibitor-induced psoriasis: A decade of experience at the Cleveland Clinic.
    Mazloom SE; Yan D; Hu JZ; Ya J; Husni ME; Warren CB; Fernandez AP
    J Am Acad Dermatol; 2020 Dec; 83(6):1590-1598. PubMed ID: 30576759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases.
    Buckley LH; Xiao R; Perman MJ; Grossman AB; Weiss PF
    Arthritis Care Res (Hoboken); 2021 Feb; 73(2):215-220. PubMed ID: 31646743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
    Kopp TI; Delcoigne B; Arkema EV; Jacobsen RK; Magyari M; Ibfelt EH; Locht H; Sellebjerg F; Cordtz RL; Jensen DV; Askling J; Dreyer L
    Ann Rheum Dis; 2020 May; 79(5):566-572. PubMed ID: 32161058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
    Izadi Z; Brenner EJ; Mahil SK; Dand N; Yiu ZZN; Yates M; Ungaro RC; Zhang X; Agrawal M; Colombel JF; Gianfrancesco MA; Hyrich KL; Strangfeld A; Carmona L; Mateus EF; Lawson-Tovey S; Klingberg E; Cuomo G; Caprioli M; Cruz-Machado AR; Mazeda Pereira AC; Hasseli R; Pfeil A; Lorenz HM; Hoyer BF; Trupin L; Rush S; Katz P; Schmajuk G; Jacobsohn L; Seet AM; Al Emadi S; Wise L; Gilbert EL; Duarte-García A; Valenzuela-Almada MO; Isnardi CA; Quintana R; Soriano ER; Hsu TY; D'Silva KM; Sparks JA; Patel NJ; Xavier RM; Marques CDL; Kakehasi AM; Flipo RM; Claudepierre P; Cantagrel A; Goupille P; Wallace ZS; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Robinson PC; Machado PM; Griffiths CEM; Barker JN; Smith CH; Yazdany J; Kappelman MD; ;
    JAMA Netw Open; 2021 Oct; 4(10):e2129639. PubMed ID: 34661663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
    Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
    Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
    Lee MP; Desai RJ; Jin Y; Brill G; Ogdie A; Kim SC
    JAMA Dermatol; 2019 Jun; 155(6):700-707. PubMed ID: 30916734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.
    Ljung L; Askling J; Rantapää-Dahlqvist S; Jacobsson L;
    Arthritis Res Ther; 2014 Jun; 16(3):R127. PubMed ID: 24941916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study.
    Barbulescu A; Delcoigne B; Askling J; Frisell T
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32669452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.
    Esse S; Mason KJ; Green AC; Warren RB
    JAMA Dermatol; 2020 Jul; 156(7):787-794. PubMed ID: 32432649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark.
    Burisch J; Jess T; Egeberg A
    Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2704-2712.e3. PubMed ID: 30936024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs).
    Paul D; Patil D; McDonald L; Patel V; Lobo F
    J Med Econ; 2020 Sep; 23(9):1025-1031. PubMed ID: 32427547
    [No Abstract]   [Full Text] [Related]  

  • 18. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
    Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
    PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Disease and Risk of Immune Mediated Inflammatory Diseases.
    Ward D; Nyboe Andersen N; Gørtz S; Thorn Iversen A; Højgaard Allin K; Beaugerie L; Kirchgesner J; Jess T
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):135-143.e8. PubMed ID: 37442315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
    Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
    Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.